Phil McEwan
YOU?
Author Swipe
View article: The evolving burden of obesity in the US: a novel population-level system dynamics approach
The evolving burden of obesity in the US: a novel population-level system dynamics approach Open
Preventing obesity is preferable to managing prevalent obesity, with superior holistic benefits, especially if focused on younger people.
View article: NHS 10 year plan: Can using AI offer a solution to the NHS’ problems?
NHS 10 year plan: Can using AI offer a solution to the NHS’ problems? Open
View article: The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes Open
The health economic value of insulin is usually expressed within a cost‐effectiveness framework providing an estimated incremental cost per quality‐adjusted life year (QALY) gained. Insulin clinical trials adopt a treat‐to‐target design in…
View article: Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes Open
Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.
View article: Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model
Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model Open
Aims Recommendations on the use of newer type 2 diabetes (T2D) treatments (e.g., SGLT2 inhibitors and GLP‐1 receptor agonists [RA]) in contemporary clinical guidelines necessitate a change in how T2D models approach therapy selection and e…
View article: Estimating the Future Burden of T2D - A System Dynamics Model
Estimating the Future Burden of T2D - A System Dynamics Model Open
View article: Global barriers to decision makers for prioritizing interventions for obesity
Global barriers to decision makers for prioritizing interventions for obesity Open
View article: The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes Open
View article: The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?
The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change? Open
View article: Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge Open
View article: The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis Open
Background Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse …
View article: Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of <scp>DAPA‐HF</scp> and <scp>DELIVER</scp> data
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of <span>DAPA‐HF</span> and <span>DELIVER</span> data Open
Aim To assess the cost‐effectiveness of dapagliflozin in addition to usual care, compared with usual care alone, in a large population of patients with heart failure (HF), spanning the full range of left ventricular ejection fraction (LVEF…
View article: Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial Open
Background The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial enrolled patients with estimated glomerular filtration rate 25–75 mL/min/1.73 m2 and urine albumin-to-creatinine ratio >200 mg/g. The Dapagliflozin …
View article: Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis Open
Dapagliflozin was approved for use in patients with chronic kidney disease (CKD) based on results of the DAPA-CKD trial, demonstrating attenuation of CKD progression and reduced risk of cardio-renal outcomes and all-cause mortality (ACM) v…
View article: The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A <scp>European</scp> health‐economic analysis of the <scp>DELIVER</scp> trial
The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A <span>European</span> health‐economic analysis of the <span>DELIVER</span> trial Open
Aims To determine the cost‐effectiveness of dapagliflozin, added to usual care, in patients with heart failure (HF) with mildly reduced or preserved ejection fraction for the UK, German and Spanish payers using detailed patient‐level data …
View article: #5431 THE VALUE OF MANAGING DIABETIC KIDNEY DISEASE: CONTRASTING FINDINGS FROM THE INDIVIDUAL PATIENT AND POPULATION LEVEL PERSPECTIVES
#5431 THE VALUE OF MANAGING DIABETIC KIDNEY DISEASE: CONTRASTING FINDINGS FROM THE INDIVIDUAL PATIENT AND POPULATION LEVEL PERSPECTIVES Open
Background and Aims The management of diabetic kidney disease (DKD) is associated with considerable resource utilisation. Within the context of the broader healthcare system, understanding the health economic implications of adopting strat…
View article: Estimating the value of <scp>sodium‐glucose cotransporter‐2</scp> inhibitors within the context of contemporary guidelines and the totality of evidence
Estimating the value of <span>sodium‐glucose cotransporter‐2</span> inhibitors within the context of contemporary guidelines and the totality of evidence Open
Aims To comprehensively estimate the cost‐effectiveness of sodium glucose cotransporter‐2 (SGLT2) inhibitor usage in the management of type 2 diabetes mellitus (T2DM) at established clinical review points, incorporating the totality of pro…
View article: Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation Open
Aims Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and improved quality of life when used to treat ID at discharge in …
View article: Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure
Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure Open
Aims To compare the cost‐effectiveness of immediate and 12‐month delayed initiation of dapagliflozin treatment in patients with a history of hospitalization for heart failure (HHF) from the UK, Canadian, German, and Spanish healthcare pers…
View article: Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study
Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study Open
This study provides further evidence of the potential cost savings achievable by treating ID with FCM at discharge in patients hospitalized for AHF with LVEF <50%. The value of FCM treatment within the healthcare systems of the UK, Switzer…
View article: MSR16 Mixture-Cure Modelling of Overall Survival of Patients With Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab + Ipilimumab in CheckMate 277 – Updated With 5 Years of Follow-up
MSR16 Mixture-Cure Modelling of Overall Survival of Patients With Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab + Ipilimumab in CheckMate 277 – Updated With 5 Years of Follow-up Open
View article: Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease Open
Background and objectives CKD imposes a significant burden on patients and health care providers, particularly upon reaching kidney failure when patients may require KRT. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CK…
View article: Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis Open
Background The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuri…
View article: Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration Open
View article: Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden Open
View article: Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China
Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China Open
Introduction Once-daily and once-weekly injectable glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) are established in obesity and type 2 diabetes mellitus (T2DM). In T2DM, both once-daily and once-weekly insulin are expected…
View article: Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial
Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial Open
Aims To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective. Cost–effectiveness and cost–utility of ticagrelor were evaluated in the o…
View article: The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program
The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program Open
The vaccination program is reducing the burden of COVID-19. However, recently, COVID-19 infections have been increasing across Europe, providing evidence that vaccine efficacy is waning. Consequently, booster doses are required to restore …
View article: Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies
Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies Open
BACKGROUND: Currently, concerted efforts to identify, prevent, and treat type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD) comorbidities are lacking at the institutional level, with emphasis place…
View article: Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example
Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example Open
Debate persists around the risk–benefit balance of vaccinating adolescents and children against COVID-19. Central to this debate is quantifying the contribution of adolescents and children to the transmission of SARS-CoV-2, and the potenti…